IMX-110 + anti-PD-1 Combination Produced Extended Median Survival in Genetic Pancreatic Cancer Mouse Model, Bolstering Planned 2022 IMX-110 Combination Clinical Trial Rationale
Immix Biopharma, Inc. (NASDAQ:IMMX)
Format
PNG
Source
Immix Biopharma, Inc.